Navigation Links
Investors Applaud Amgen and Novartis for Support of Investor Principles on Biosimilars, Alternatives to Higher Cost Drugs
Date:8/11/2014

DETROIT, Aug. 11, 2014 /PRNewswire/ -- A coalition of 19 institutional investors representing $430 billion in assets commends Amgen and Novartis for support of a set of investor principles to guide corporate boards on policy and oversight responsibilities related to biosimilar activities. The principles, included in the coalition's Investor Statement on Board Oversight of Biosimilar Issues, call on boards to ensure that information provided to policymakers on patient safety is balanced, investor dollars used for political lobbying is aligned with shareholder interests, and disclosure on significant business partnerships is transparent.  Biosimilars are biologic medical products whose active drug substance is derived from a living organism and used to treat serious illnesses including cancer, rheumatoid arthritis, and multiple sclerosis.  

In responses to the coalition, the two companies expressly affirmed support for the principles and noted existing policies and practices that also advance the principles.  Amgen and Sandoz are the first to recognize the principles as part of an on-going initiative, led by the UAW Retiree Medical Benefits Trust, to engage 25 of the largest pharmaceutical companies on the issue of biosimilars.

The company responses come at an important time when biosmilar market activity appears to be heating up in the U.S.  On July 24, 2014, Sandoz, a division of Novartis, became the first company to file for U.S. biosimilar approval under the FDA's rules for biosimilars included in the Biologics Price Competition and Innovation Act of 2009.  Sandoz's filing seeks approval for a biosimilar of Amgen's Neupogen, a biologic drug used to fight infection in patients undergoing chemotherapy."As long-term investors, we are very pleased that the companies support the investor principles," said Meredith Miller, Chief Corporate Governance Officer, UAW Retiree Medical Benefits Trust.  "Corporate behavior that encourages innovation, transparency, patient safety and access is the financial engine of the healthcare sector."

"We rely on the board of directors to ensure that these corporate governance best practices inform the range of company activities related to biosimilars," said William Atwood, Executive Director of the Illinois State Board of Investments.  "As financial stewards for our beneficiaries, it is our responsibility to communicate these expectations to our company directors."

While new to the U.S., biosimilars play an important role in the European healthcare markets where 14 biosimilars have been marketed since 2006 with no patient safety issues, according to the European Medicines Agency. 

"The investor principles reinforce the need for balanced and transparent information as biosimilars markets continue to expand globally," said Manuel Isaza of Hermes Equity Ownership Services.

"We view these best corporate governance practices as guideposts for future company engagements on biosimilars and for setting expectations going forward," said Lauren Compere, Managing Director, Boston Common Asset Management, LLC.

The Investor Statement is available via this link:
click here to see.

Members of the investor coalition include: AFL-CIO Office of Investment

Massachusetts Laborers Benefit FundsAFT Retirement Plan & Trust

Mercy Investment Services, Inc.Bon Secours Health Systems, Inc.

Middletown Works Hourly & Salaried Union Retirees Health Care FundBoston Common Asset Management

New York Common Retirement FundCalvert Investments

Northwest Coalition for Responsible InvestmentCHE Trinity Health

The Nathan Cummings FoundationDominican Sisters of Hope

Trillium Asset Management, LLCHermes Equity Ownership Services

UAW Retiree Medical Benefits TrustIllinois State Board of Investment

Ursuline Sisters of Tildonk, U.S. Province Marco Consulting Group
'/>"/>

SOURCE UAW Retiree Medical Benefits Trust
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Metabolix, Inc. Enters into Private Placement Agreement with Investors to Raise $25 Million in Equity Financing
2. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL
3. DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities
4. Expanded SPIE Photonics West 2014 Industry Track Offers More for Technology Commercialization Entrepreneurs, Startups, Investors, Executives
5. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ambit Biosciences Corporation. - AMBI
6. OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call
7. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
8. Spherix Announces Private Placement as the Company Continues to Execute its Patent Monetization Program - Spherix accepts $2.0 Million from Investors
9. ThromboGenics Establishes Level 1 ADR Program for US Investors
10. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In OvaScience, Inc. To Contact The Firm
11. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Trius Therapeutics, Inc. - TSRX
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2018)... ... September 11, 2018 , ... Leading regenerative ... of Feline Practitioners Conference (AAFP) later this month. The company’s CEO ... therapy for the treatment of chronic kidney disease in felines at a poster ...
(Date:9/12/2018)... ... 12, 2018 , ... NDA Partners Chairman Carl Peck, MD, ... of Regulatory Affairs and Quality Systems at WellDoc, Inc., has joined the firm ... Quality Systems at WellDoc, Inc., she conducted quality control and supplier audits, led ...
(Date:9/7/2018)... ... 06, 2018 , ... The Discovery on Target (DOT) conference ... industry’s preeminent event on novel drug targets.” BellBrook Labs’ high throughput screening (HTS) ... emerging targets in a quest to find new treatments for disease. , BellBrook ...
(Date:9/7/2018)... ... 2018 , ... Flagship Biosciences’ MuscleMap algorithm that supports therapeutic ... effective as manual pathology. The study, “Validation of a Muscle-Specific Tissue Image-Analysis Tool ... the Archives of Pathology & Laboratory Medicine on August 31, 2018. Download the ...
Breaking Biology Technology:
(Date:8/29/2018)... ... August 28, 2018 , ... Johanna Dwyer, founder and Chief ... of excellence in the field of intellectual property, and named Daniela Sanchez as ... IP Award aims to encourage and support women in their pursuit of careers ...
(Date:8/29/2018)... ... August 29, 2018 , ... ... technology to identify specific chromosomal abnormalities using morphological assessment through artificial intelligence ... and Australia-based Life Whisperer suggests that artificial intelligence (AI) models, ...
(Date:8/26/2018)... ... August 24, 2018 , ... ... clinical diagnostic laboratories. However, this technology introduces many well-described challenges around data ... leads the South London NHS Genomic Medicine Centre. The Viapath Genetics Laboratories ...
Breaking Biology News(10 mins):